Hoth Therapeutics (NASDAQ: HOTH) is a clinical-stage biopharmaceutical company that develops topical and other therapeutic product candidates for skin conditions, Alzheimer's disease, and related indications. The company generates no product revenue and funds operations entirely through equity and debt issuances, including common stock offerings and warrant exercises. Hoth holds an exclusive license from the University of Cincinnati for the BioLexa Platform, a topical composition targeting biofilm formation, and has a sponsored research agreement with Washington University in St. Louis for HT-ALZ, a candidate targeting Alzheimer's disease markers. Research and development expenses were approximately $3.2 million for the year ended December 31, 2024, with HT-001 accounting for approximately $2.1 million of that total. General and administrative expenses were approximately $6.4 million for the year ended December 31, 2025. Hoth carries an accumulated deficit and relies on external financing to continue operations, with milestone payment obligations of up to approximately $25 million across current license agreements if all milestones are achieved.

Revenue model

No product revenue as of the 10-K filed 2026-03-27. Operations are funded through sales of equity and debt securities, including common stock and warrant exercises. Future revenue, if any, would come from product sales, royalties, or partnership arrangements following regulatory approval of product candidates.

Products and services

HT-001: topical candidate in manufacturing and clinical activities ($2.1 million R&D spend, year ended December 31, 2024). HT-KIT: candidate in manufacturing and preclinical activities ($0.6 million, year ended December 31, 2024). HT-ALZ: preclinical Alzheimer's disease candidate targeting NK-1Rs ($0.2 million, year ended December 31, 2024); formulation development initiated in 2024. HT-004: candidate in sponsored research ($0.1 million, year ended December 31, 2024). BioLexa Platform: exclusively licensed from University of Cincinnati; topical compositions using zinc chelators and gentamicin targeting biofilm formation.

Customers and end markets

No commercial customers as of the filing date. Target end markets include dermatology patients and Alzheimer's disease patients, subject to future regulatory approval. Potential payors include Medicare, Medicaid, and private insurers.

Value-chain role

Early-stage drug developer. Hoth in-licenses technology from universities, conducts preclinical and clinical research through contract research organizations and investigative sites, and has not yet reached manufacturing or commercialization at scale.

Geographic exposure

Incorporated and headquartered in the United States. Exclusive forum provision designates the Eighth Judicial District Court of Clark County, Nevada for state law claims, indicating Nevada incorporation. No geographic revenue breakdown disclosed in the filing excerpts.

Source: SEC 10-K, filed 2026-03-27

Industry: Pharmaceutical Preparations Peers: AGILE THERAPEUTICS INC Aytu Biopharma Inc Barrel Energy Inc. Cingulate Inc Jaguar Health Inc Johnson & Johnson Pulmatrix Inc Unrivaled Brands, Inc. Weed Inc Virpax Pharmaceuticals, Inc.